A Randomised, Single-blind, Placebo-controlled Trial in Parallel Group Design to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 1356225 Administered as Oral Solution and Tablets to Healthy Male Subjects, and a Randomised, Open-label, Single-dose, Two-way Cross-over Bioavailability Comparison of BI 1356225 as Tablet With and Without Food
Latest Information Update: 21 Jan 2020
At a glance
- Drugs BI 1356225 (Primary)
- Indications Unspecified
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 15 Jan 2020 Status changed from active, no longer recruiting to completed.
- 28 Nov 2019 Status changed from recruiting to active, no longer recruiting.
- 11 Nov 2019 Planned End Date changed from 18 Dec 2019 to 19 Dec 2019.